Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CRVO 
CervoMed Inc. (CRVO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: CRVO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $20
1 Year Target Price $20
| 5 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 131.1% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 74.07M USD | Price to earnings Ratio - | 1Y Target Price 20 |
Price to earnings Ratio - | 1Y Target Price 20 | ||
Volume (30-day avg) 7 | Beta -6.36 | 52 Weeks Range 1.80 - 16.94 | Updated Date 10/14/2025 |
52 Weeks Range 1.80 - 16.94 | Updated Date 10/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.63 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -290.76% | Operating Margin (TTM) -376.41% |
Management Effectiveness
Return on Assets (TTM) -33.63% | Return on Equity (TTM) -54.21% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 37570048 | Price to Sales(TTM) 9.52 |
Enterprise Value 37570048 | Price to Sales(TTM) 9.52 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.64 | Shares Outstanding 9252719 | Shares Floating 5480108 |
Shares Outstanding 9252719 | Shares Floating 5480108 | ||
Percent Insiders 31.4 | Percent Institutions 23.56 |
Upturn AI SWOT
CervoMed Inc.
Company Overview
History and Background
CervoMed Inc. is a clinical-stage company focused on developing innovative treatments for neurological diseases and cognitive impairment, particularly Alzheimer's disease and dementia. While specifics on the exact founding date and early milestones require deeper research, the company is relatively young and progressing through clinical trials.
Core Business Areas
- Drug Development: Focuses on researching and developing novel therapeutic candidates for neurological disorders.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Partnerships and Licensing: Seeks partnerships and licensing agreements to advance its drug development programs and expand its market reach.
Leadership and Structure
Information on the specific leadership team and organizational structure requires further research. Generally, a company like CervoMed would have a CEO, CFO, CSO, and a board of directors.
Top Products and Market Share
Key Offerings
- CER-001: CervoMed's lead drug candidate is CER-001, a first-in-class investigational oral small molecule. It is designed to impact multiple pathways relevant to disease modification in Alzheimer's disease. It is currently in Phase 1b/2a clinical trials. Precise market share data is currently unavailable as the product is not yet approved. Competitors include companies developing Alzheimer's therapies, such as Biogen (BIIB), Eli Lilly (LLY) and Eisai (ESALY).
Market Dynamics
Industry Overview
The pharmaceutical industry focused on neurological diseases is experiencing significant growth due to an aging population and increasing prevalence of conditions like Alzheimer's and dementia. There is a high unmet need for effective treatments.
Positioning
CervoMed is positioned as an innovator in the neurological disease therapeutics space, focusing on disease-modifying approaches. They are competing with large pharmaceutical companies and smaller biotech firms.
Total Addressable Market (TAM)
The Alzheimer's disease treatment market is projected to reach billions of dollars. CervoMed's success depends on the efficacy and safety of their drug candidates, and their ability to capture a portion of the market.
Upturn SWOT Analysis
Strengths
- Novel drug candidate (CER-001)
- Focus on disease-modifying therapies
- Potential for significant impact in unmet need
Weaknesses
- Early stage clinical development
- High risk of clinical trial failure
- Limited financial resources compared to larger pharmaceutical companies
Opportunities
- Partnerships with larger pharmaceutical companies
- Fast Track or Breakthrough Therapy designation from regulatory agencies
- Positive clinical trial results
Threats
- Clinical trial failures
- Competition from other companies developing Alzheimer's therapies
- Regulatory hurdles
- Financing risks
Competitors and Market Share
Key Competitors
- BIIB
- LLY
- ESALY
- ABBV
Competitive Landscape
CervoMed faces intense competition from established pharmaceutical companies and other biotech firms pursuing Alzheimer's therapies. Success depends on differentiating CER-001 through superior efficacy and safety.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited as the company is in the early stages of product development.
Future Projections: Future growth is contingent on successful clinical trial outcomes and regulatory approval of CER-001. Analyst estimates are not widely available at this early stage.
Recent Initiatives: Recent initiatives likely involve progressing CER-001 through clinical trials and securing funding.
Summary
CervoMed is a high-risk, high-reward clinical-stage company focused on developing a novel Alzheimer's treatment. Its success hinges on the outcome of its clinical trials for CER-001. The company's small size and limited resources present challenges compared to larger competitors. Positive clinical data or a partnership could significantly improve its prospects, while clinical trial failures could negatively impact its value.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings (when available)
- Press releases
- Industry reports
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is estimated and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CervoMed Inc.
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2016-01-04 | Co-Founder, CEO, President & Director Dr. John J. Alam M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 15 | Website https://www.cervomed.com |
Full time employees 15 | Website https://www.cervomed.com | ||
CervoMed Inc., a a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. It is being evaluated in a Phase 2b study in patients with DLB. The company develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.